FineHeart has raised €83m ($96.6m) in public and private financing towards advancing the development of its implantable cardiac output accelerator for advanced heart failure treatment. The French clinical stage company’s lead product in development is Flowmaker, a hybrid between a pacemaker and a cardiac assist device to restore normal contraction of the heart. €35m ($40.7m) of the total funds originate from the close of FineHeart’s Series C funding round. The round featured participation from new inves ...